{"protocolSection": {"identificationModule": {"nctId": "NCT02571777", "orgStudyIdInfo": {"id": "CQVM149B2302"}, "secondaryIdInfos": [{"id": "2015-002899-25", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma", "officialTitle": "A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2020-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-06-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-06-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-10-05", "studyFirstSubmitQcDate": "2015-10-07", "studyFirstPostDateStruct": {"date": "2015-10-08", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-06-12", "resultsFirstSubmitQcDate": "2020-07-16", "resultsFirstPostDateStruct": {"date": "2020-07-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-07-16", "lastUpdatePostDateStruct": {"date": "2020-07-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 \u03bcg and QVM149 150/50/160 \u03bcg via Concept1) over two respective QMF149 doses (QMF149 150/160 \u03bcg and QMF149 150/320) \u03bcg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.", "detailedDescription": "This study used a 52-week treatment, randomized, double-blind, double-dummy, parallel-group design. A total of 3092 asthma patients were randomized into the 5 treatment groups with a randomization ratio of 1:1:1:1:1 (approximately 617 patients per treatment group): QVM149 150/50/80 \u03bcg once daily (o.d.), QVM149 150/50/160 \u03bcg o.d., QMF149 150/160 \u03bcg o.d. and QMF149 150/320 \u03bcg o.d., all delivered via the Concept1 device, and salmeterol/fluticasone 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler. The 52 week treatment period was followed by a 30-day Follow-up.\n\nThe primary objective of this study was to demonstrate superiority of either QVM149 150/50/80 \u03bcg o.d. to QMF149 150/160 \u03bcg o.d. or QVM149 150/50/160 \u03bcg o.d. to QMF149 150/320 \u03bcg o.d in terms of trough Forced Expiratory Volume in One Second (Trough FEV1) (FEV1) at Week 26, all delivered via Concept1."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "QVM149", "QMF149"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 3092, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QVM149 150/50/160 \u00b5g o.d.", "type": "EXPERIMENTAL", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "interventionNames": ["Drug: QVM149 150/50/160"]}, {"label": "QVM149 150/50/80 \u00b5g o.d.", "type": "EXPERIMENTAL", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "interventionNames": ["Drug: QVM149 150/50/80"]}, {"label": "QMF149 150/320 \u00b5g o.d.", "type": "ACTIVE_COMPARATOR", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "interventionNames": ["Drug: QMF149 150/320"]}, {"label": "QMF149 150/160 \u00b5g o.d.", "type": "ACTIVE_COMPARATOR", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "interventionNames": ["Drug: QMF149 150/160"]}, {"label": "Salmeterol/fluticasone 50/500 \u03bcg b.i.d.", "type": "ACTIVE_COMPARATOR", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae", "interventionNames": ["Drug: salmeterol/fluticasone"]}], "interventions": [{"type": "DRUG", "name": "QVM149 150/50/160", "armGroupLabels": ["QVM149 150/50/160 \u00b5g o.d."]}, {"type": "DRUG", "name": "QVM149 150/50/80", "armGroupLabels": ["QVM149 150/50/80 \u00b5g o.d."]}, {"type": "DRUG", "name": "QMF149 150/320", "armGroupLabels": ["QMF149 150/320 \u00b5g o.d."]}, {"type": "DRUG", "name": "QMF149 150/160", "armGroupLabels": ["QMF149 150/160 \u00b5g o.d."]}, {"type": "DRUG", "name": "salmeterol/fluticasone", "armGroupLabels": ["Salmeterol/fluticasone 50/500 \u03bcg b.i.d."]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.\n\nThe primary endpoint considered the following 2 comparison groups:\n\n* QVM149 150/50/80 \u03bcg o.d. compared with QMF149 150/160 \u03bcg o.d. both delivered via Concept1\n* QVM149 150/50/160 \u03bcg o.d. compared with QMF149 150/320 \u03bcg o.d. both delivered via Concept1.", "timeFrame": "26 weeks"}], "secondaryOutcomes": [{"measure": "Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means \\> 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means \\< 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control.", "timeFrame": "26 weeks, 52 weeks"}, {"measure": "Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.\n\nThis secondary endpoint considered the following 2 comparison groups:\n\n* QVM149 150/50/80 \u03bcg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 \u03bcg b.i.d. via Accuhaler\u00ae\n* QVM149 150/50/160 \u03bcg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 \u03bcg b.i.d. via Accuhaler\u00ae", "timeFrame": "26 weeks"}, {"measure": "Trough FEV1 at Week 52", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", "timeFrame": "52 weeks"}, {"measure": "Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12", "description": "Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test.", "timeFrame": "4 weeks, 12 weeks"}, {"measure": "Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks", "description": "FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.", "timeFrame": "Up to Week 52"}, {"measure": "Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment", "description": "PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.", "timeFrame": "Baseline, 26 weeks, 52 weeks"}, {"measure": "Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was \"How did you sleep last night?\" had to be answered with \"I did not wake up because of any breathing problems\" with scores from 0 (no problem)-4 (very severe problems).", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was \"How did you sleep last night?\" had to be answered with \"I did not wake up because of any breathing problems\" with scores from 0 (no problem)-4 (very severe problems).", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks", "description": "Percentage of days without rescue medication usage (100 \u03bcg salbutamol/90 \u03bcg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment.", "timeFrame": "Baseline, 26 weeks, 52 weeks"}, {"measure": "Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ \u2265 0.5 at Week 26 and Week 52", "description": "Change from baseline in ACQ-7 scores of \u2264 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means \\> 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means \\< 50% of predicted FEV1). The total score was calculated as the mean of all questions.", "timeFrame": "26 weeks, 52 weeks"}, {"measure": "Time to First Hospitalization for Asthma Exacerbation", "description": "Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).", "timeFrame": "52 weeks on average, up to 416 days"}, {"measure": "Time to First Asthma Exacerbation by Exacerbation Category", "description": "Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).\n\nThe exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.", "timeFrame": "52 weeks on average, up to 416 days"}, {"measure": "Annual Rate of Asthma Exacerbations by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "timeFrame": "52 weeks"}, {"measure": "Duration in Days of Asthma Exacerbations by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "timeFrame": "Up to Week 52"}, {"measure": "Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "timeFrame": "Up to Week 52"}, {"measure": "Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation", "description": "Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event.", "timeFrame": "52 weeks on average, up to 416 days"}, {"measure": "Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations", "description": "The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.", "timeFrame": "Up to Week 52"}, {"measure": "Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks", "description": "All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.", "timeFrame": "Baseline, 26 weeks, 52 weeks"}, {"measure": "Asthma Quality of Life Questionnaire (AQLQ) at Week 52", "description": "AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:\n\n* Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)\n* Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)\n* Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)\n* Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)\n* Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.", "timeFrame": "52 weeks"}, {"measure": "Pre-dose FEV1 at Weeks 4 and 12", "description": "Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", "timeFrame": "4 weeks, 12 weeks"}, {"measure": "Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes", "description": "A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.", "timeFrame": "Up to Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior to Visit 1 (Screening).\n* Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable medium or high doses of ICS/LABA for at least 1 month prior to Visit 1.\n* Patients must be symptomatic at screening despite treatment with mid or high stable doses of ICS/LABA. Patients with ACQ-7 score \u2265 1.5 at Visit 101 and at Visit 102 (before randomization).\n* Patients with documented history of at least one asthma exacerbation which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1, and required systemic corticosteroid treatment.\n* Pre-bronchodilator FEV1 of \\< 80 % of the predicted normal value for the patient according to ATS/ERS guidelines after withholding bronchodilators at both visits 101 and 102.\n* Withholding period of bronchodilators prior to spirometry: SABA for \u2265 6 hrs, Twice daily LABA (or FDC of ICS/LABA) for \u2265 12 hrs, Once daily LABA (or FDC of ICS/LABA) for \u2265 24 hrs, SAMA for \u2265 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines for 24 hrs, .\n* Washout period of each drug should be kept as close as possible as above and should not be longer. If longer washout period is needed due to scheduling issues, please contact Novartis Medical monitor.\n* A one-time repeat of percentage predicated FEV1 (Pre-bronchodilator) at Visit 101 and/or Visit 102 is allowed in an ad-hoc visit. Repeat of Visit 101 spirometry should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before randomization. Run-in medication should be dispensed once spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 % predicted normal value, and reversibility) as per equipment\n* A one-time rescreen is allowed in case the patient fails to meet the criteria at the repeat, provided the patient returned to the required treatment as per inclusion criteria 4\n* Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 \u00b5g salbutamol/360 \u00b5g albuterol (or equivalent dose) at Visit 101.All patients must perform a reversibility test at Visit 101. If reversibility is not demonstrated at Visit 101 then one of the following criteria need to be met.\n* Reversibility should be repeated once.\n* Patients may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.\n* Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1. If reversibility is not demonstrated at Visit 101 (or after repeated assessment in an ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not available (or was not performed according to the ATS/ERS guidelines patients must be screen failed\n* Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing\n\nExclusion Criteria:\n\n* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation.\n* Patients who have ever required intubation for a severe asthma attack/exacerbation.\n* Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.\n* Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).\n* Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered).\n* Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.\n* Patients with evidence upon visual inspection (laboratory culture is not required) of clinically significant (in the opinion of investigator) oropharyngeal candidiasis at Visit 102 or earlier, with or without treatment. Patients may be re-screened once their candidiasis has been treated and has resolved.\n* Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.\n* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.\n* Patients with Type I diabetes or uncontrolled Type II diabetes.\n* Patients who, either in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition such as (but not limited to) unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.\n* Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a resting ventricular rate \\< 100/min. At Visit 101 the atrial fibrillation must be confirmed by central reading.\n* Patients with a history of myocardial infarction (this should be confirmed clinically by the investigator) within the previous 12 months.\n* Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study\n* Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (\\> 450 msec for males and \\> 460 msec for females) and confirmed by a central assessor (these patients should not be rescreened).\n* Patients with a history of hypersensitivity to lactose, any of the study drugs or to similar drugs within the class including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.\n* Patients who have not achieved an acceptable spirometry result at Visit 101 in accordance with ATS/ERS criteria for acceptability and repeatability. A one-time repeat spirometry is allowed in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day) if the spirometry did not qualify due to ATS/ERS criteria at Visit 101 and/or Visit 102. If the patient fails the repeat assessment, the patient may be rescreened once, provided the patient returns to the required treatment as per inclusion criteria 4.\n* Patients unable to use the Concept1 dry powder inhaler, Accuhaler or a metered dose inhaler. Spacer devices are not permitted.\n* History of alcohol or other substance abuse.\n* Patients with a known history of non-compliance to medication or who were unable or unwilling to complete a patient diary or who are unable or unwilling to use Electronic Peak Flow with e-diary device.\n* Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Bahia Blanca", "state": "Buenos Aires", "zip": "8000", "country": "Argentina", "geoPoint": {"lat": -38.71959, "lon": -62.27243}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1056ABJ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Florida", "state": "Buenos Aires", "zip": "B1602DQD", "country": "Argentina"}, {"facility": "Novartis Investigative Site", "city": "Lanus", "state": "Buenos Aires", "zip": "B8000XAV", "country": "Argentina", "geoPoint": {"lat": -34.70252, "lon": -58.3955}}, {"facility": "Novartis Investigative Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Novartis Investigative Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "B7600FZN", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "Novartis Investigative Site", "city": "Nueve de Julio", "state": "Buenos Aires", "zip": "B6500EZL", "country": "Argentina", "geoPoint": {"lat": -35.44437, "lon": -60.88313}}, {"facility": "Novartis Investigative Site", "city": "San Nicolas", "state": "Buenos Aires", "zip": "B2900JUB", "country": "Argentina"}, {"facility": "Novartis Investigative Site", "city": "Vicente Lopez", "state": "Buenos Aires", "zip": "B1602DOH", "country": "Argentina", "geoPoint": {"lat": -34.52947, "lon": -58.4737}}, {"facility": "Novartis Investigative Site", "city": "Villa Maria", "state": "Cordoba", "zip": "X5900JKA", "country": "Argentina", "geoPoint": {"lat": -32.40751, "lon": -63.24016}}, {"facility": "Novartis Investigative Site", "city": "Concepcion del Uruguay", "state": "Entre Rios", "zip": "3260", "country": "Argentina", "geoPoint": {"lat": -32.48249, "lon": -58.23722}}, {"facility": "Novartis Investigative Site", "city": "Godoy Cruz", "state": "Mendoza", "zip": "M5500EOB", "country": "Argentina", "geoPoint": {"lat": -32.92863, "lon": -68.8351}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "state": "Rosario", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000DSV", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000JKR", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000QID", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "zip": "4000", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "B1646EBJ", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "B1842DID", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "C1120AAC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "C1125ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Cordoba", "zip": "5000", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novartis Investigative Site", "city": "Cordoba", "zip": "X5003DCE", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novartis Investigative Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Novartis Investigative Site", "city": "Mendoza", "zip": "M5500CBA", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Novartis Investigative Site", "city": "Parana", "zip": "3100", "country": "Argentina", "geoPoint": {"lat": -31.73197, "lon": -60.5238}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "zip": "S3000FIL", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "zip": "S3000FWO", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Bludenz", "zip": "6700", "country": "Austria", "geoPoint": {"lat": 47.15476, "lon": 9.82255}}, {"facility": "Novartis Investigative Site", "city": "Feldbach", "zip": "8330", "country": "Austria", "geoPoint": {"lat": 46.95306, "lon": 15.88833}}, {"facility": "Novartis Investigative Site", "city": "Feldkirch", "zip": "6800", "country": "Austria", "geoPoint": {"lat": 47.23306, "lon": 9.6}}, {"facility": "Novartis Investigative Site", "city": "Grieskirchen", "zip": "4710", "country": "Austria", "geoPoint": {"lat": 48.23333, "lon": 13.83333}}, {"facility": "Novartis Investigative Site", "city": "Gosselies", "state": "BEL", "zip": "6041", "country": "Belgium", "geoPoint": {"lat": 50.46936, "lon": 4.43324}}, {"facility": "Novartis Investigative Site", "city": "Hasselt", "state": "BEL", "zip": "3500", "country": "Belgium", "geoPoint": {"lat": 50.93106, "lon": 5.33781}}, {"facility": "Novartis Investigative Site", "city": "Jette", "state": "Brussel", "zip": "1090", "country": "Belgium", "geoPoint": {"lat": 50.87309, "lon": 4.33419}}, {"facility": "Novartis Investigative Site", "city": "Braine L Alleud Waterloo", "zip": "1420", "country": "Belgium"}, {"facility": "Novartis Investigative Site", "city": "Bruxelles", "zip": "1000", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Bruxelles", "zip": "1070", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Eghezee", "zip": "5310", "country": "Belgium", "geoPoint": {"lat": 50.59076, "lon": 4.91175}}, {"facility": "Novartis Investigative Site", "city": "Erpent", "zip": "5100", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "Novartis Investigative Site", "city": "Lebbeke", "zip": "9280", "country": "Belgium", "geoPoint": {"lat": 51.00464, "lon": 4.13457}}, {"facility": "Novartis Investigative Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Novartis Investigative Site", "city": "Malmedy", "zip": "4960", "country": "Belgium", "geoPoint": {"lat": 50.42686, "lon": 6.02794}}, {"facility": "Novartis Investigative Site", "city": "Plovdiv", "state": "BGR", "zip": "4000", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"facility": "Novartis Investigative Site", "city": "Ruse", "zip": "7002", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Novartis Investigative Site", "city": "Sofia", "zip": "1202", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novartis Investigative Site", "city": "Sofia", "zip": "1463", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novartis Investigative Site", "city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"facility": "Novartis Investigative Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8H 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Novartis Investigative Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Novartis Investigative Site", "city": "Toronto", "state": "Ontario", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novartis Investigative Site", "city": "Toronto", "state": "Ontario", "zip": "M6H 3M2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novartis Investigative Site", "city": "Toronto", "state": "Ontario", "zip": "M9V 4B4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Novartis Investigative Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 2G1", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Novartis Investigative Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 5A6", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Novartis Investigative Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1L5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novartis Investigative Site", "city": "Sherbrooke", "state": "Quebec", "zip": "J1H 5N4", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Novartis Investigative Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Novartis Investigative Site", "city": "Victoriaville", "state": "Quebec", "zip": "G6P 6P6", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -71.96579}}, {"facility": "Novartis Investigative Site", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "state": "Region Metropolitana", "zip": "7500692", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Valparaiso", "state": "TX", "zip": "2341131", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Novartis Investigative Site", "city": "Curico", "state": "VII Region Del Maule", "zip": "3341643", "country": "Chile", "geoPoint": {"lat": -34.98279, "lon": -71.23943}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "zip": "9100", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Novartis Investigative Site", "city": "Haikou", "state": "Hainan", "zip": "570311", "country": "China", "geoPoint": {"lat": 20.04583, "lon": 110.34167}}, {"facility": "Novartis Investigative Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210009", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novartis Investigative Site", "city": "Suzhou", "state": "Jiangsu", "zip": "215006", "country": "China", "geoPoint": {"lat": 31.30408, "lon": 120.59538}}, {"facility": "Novartis Investigative Site", "city": "Chang Chun", "state": "Jilin", "zip": "130021", "country": "China", "geoPoint": {"lat": 42.74694, "lon": 126.24667}}, {"facility": "Novartis Investigative Site", "city": "Shenyang", "state": "Liaoning", "zip": "110000", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novartis Investigative Site", "city": "Shenyang", "state": "Liaoning", "zip": "110003", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novartis Investigative Site", "city": "Shenyang", "state": "Liaoning", "zip": "110011", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novartis Investigative Site", "city": "Shanghai", "state": "Shanghai", "zip": "200032", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novartis Investigative Site", "city": "Xian", "state": "Shanxi", "zip": "710061", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "Novartis Investigative Site", "city": "Chengdu", "state": "Sichuan", "zip": "610041", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Novartis Investigative Site", "city": "Chongqing", "zip": "400037", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Novartis Investigative Site", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novartis Investigative Site", "city": "Tianjin", "zip": "300052", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novartis Investigative Site", "city": "Bogota DC", "zip": "110221", "country": "Colombia"}, {"facility": "Novartis Investigative Site", "city": "Bogota", "zip": "110221", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Floridablanca", "country": "Colombia", "geoPoint": {"lat": 7.06222, "lon": -73.08644}}, {"facility": "Novartis Investigative Site", "city": "Medellin", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Novartis Investigative Site", "city": "Zagreb", "state": "HRV", "zip": "10 000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Novartis Investigative Site", "city": "Petrinja", "zip": "44250", "country": "Croatia", "geoPoint": {"lat": 45.4375, "lon": 16.29}}, {"facility": "Novartis Investigative Site", "city": "Zadar", "zip": "23000", "country": "Croatia", "geoPoint": {"lat": 44.11972, "lon": 15.24222}}, {"facility": "Novartis Investigative Site", "city": "Zagreb", "zip": "10000", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"facility": "Novartis Investigative Site", "city": "Copenhagen NV", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Novartis Investigative Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "10117", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "10138", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "13419", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tartu", "zip": "51014", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "Novartis Investigative Site", "city": "Jyvaskyla", "zip": "40100", "country": "Finland", "geoPoint": {"lat": 62.24147, "lon": 25.72088}}, {"facility": "Novartis Investigative Site", "city": "Montpellier cedex 5", "state": "Herault", "zip": "34059", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novartis Investigative Site", "city": "Bochum", "state": "Nordrhein Westfalen", "zip": "D-44787", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Novartis Investigative Site", "city": "Koblenz", "state": "NRW", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Novartis Investigative Site", "city": "Cottbus", "state": "Sachsen", "zip": "03050", "country": "Germany", "geoPoint": {"lat": 51.75769, "lon": 14.32888}}, {"facility": "Novartis Investigative Site", "city": "Geesthacht", "state": "Schleswig Holstein", "zip": "12502", "country": "Germany", "geoPoint": {"lat": 53.43575, "lon": 10.3779}}, {"facility": "Novartis Investigative Site", "city": "Annaberg-Buchholz", "zip": "09456", "country": "Germany", "geoPoint": {"lat": 50.57953, "lon": 13.00627}}, {"facility": "Novartis Investigative Site", "city": "Aschaffenburg", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10119", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12159", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12203", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13057", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13156", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Bonn", "zip": "53119", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Novartis Investigative Site", "city": "Darmstadt", "zip": "64283", "country": "Germany", "geoPoint": {"lat": 49.87167, "lon": 8.65027}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt am Main", "zip": "60313", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Halle", "zip": "06108", "country": "Germany", "geoPoint": {"lat": 51.48159, "lon": 11.97948}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "22335", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigative Site", "city": "Karlsruhe", "zip": "76137", "country": "Germany", "geoPoint": {"lat": 49.00937, "lon": 8.40444}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04357", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "L\u00fcbeck", "zip": "23558", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Mittweida", "zip": "09648", "country": "Germany", "geoPoint": {"lat": 50.98622, "lon": 12.97537}}, {"facility": "Novartis Investigative Site", "city": "Neu Isenburg", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "Novartis Investigative Site", "city": "Potsdam", "zip": "14467", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "Novartis Investigative Site", "city": "Rudersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Novartis Investigative Site", "city": "Witten", "zip": "58452", "country": "Germany", "geoPoint": {"lat": 51.44362, "lon": 7.35258}}, {"facility": "Novartis Investigative Site", "city": "Athens", "state": "GR", "zip": "115 27", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novartis Investigative Site", "city": "Thessaloniki", "state": "GR", "zip": "564 03", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novartis Investigative Site", "city": "Thessaloniki", "state": "GR", "zip": "564 29", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novartis Investigative Site", "city": "Thessaloniki", "state": "GR", "zip": "570 10", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novartis Investigative Site", "city": "Athens", "zip": "106 76", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novartis Investigative Site", "city": "Athens", "zip": "175 62", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Novartis Investigative Site", "city": "Heraklion Crete", "zip": "711 10", "country": "Greece"}, {"facility": "Novartis Investigative Site", "city": "Budaors", "state": "HUN", "zip": "2040", "country": "Hungary", "geoPoint": {"lat": 47.46181, "lon": 18.95845}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "state": "HUN", "zip": "1204", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Eger", "state": "HUN", "zip": "3300", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Novartis Investigative Site", "city": "Kapuv\u00e1r", "state": "HUN", "zip": "9330", "country": "Hungary", "geoPoint": {"lat": 47.59224, "lon": 17.02886}}, {"facility": "Novartis Investigative Site", "city": "Puspokladany", "state": "HUN", "zip": "4150", "country": "Hungary", "geoPoint": {"lat": 47.31667, "lon": 21.11667}}, {"facility": "Novartis Investigative Site", "city": "Tata", "state": "HUN", "zip": "2890", "country": "Hungary", "geoPoint": {"lat": 47.65289, "lon": 18.31838}}, {"facility": "Novartis Investigative Site", "city": "Balassagyarmat", "zip": "2660", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Novartis Investigative Site", "city": "Budapest", "zip": "1106", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Novartis Investigative Site", "city": "Godollo", "zip": "2100", "country": "Hungary", "geoPoint": {"lat": 47.59657, "lon": 19.35515}}, {"facility": "Novartis Investigative Site", "city": "Komarom", "zip": "2900", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Novartis Investigative Site", "city": "Mateszalka", "zip": "4700", "country": "Hungary", "geoPoint": {"lat": 47.95528, "lon": 22.32348}}, {"facility": "Novartis Investigative Site", "city": "Nyiregyhaza", "zip": "H-4400", "country": "Hungary", "geoPoint": {"lat": 47.95539, "lon": 21.71671}}, {"facility": "Novartis Investigative Site", "city": "Szarvas", "zip": "5540", "country": "Hungary", "geoPoint": {"lat": 46.86667, "lon": 20.55}}, {"facility": "Novartis Investigative Site", "city": "Szeged", "zip": "6722", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Novartis Investigative Site", "city": "Szeged", "zip": "6772", "country": "Hungary", "geoPoint": {"lat": 46.253, "lon": 20.14824}}, {"facility": "Novartis Investigative Site", "city": "Szigetszentmiklos", "zip": "H-2310", "country": "Hungary", "geoPoint": {"lat": 47.34382, "lon": 19.04335}}, {"facility": "Novartis Investigative Site", "city": "Szigetvar", "zip": "7900", "country": "Hungary", "geoPoint": {"lat": 46.04865, "lon": 17.80554}}, {"facility": "Novartis Investigative Site", "city": "Guntur", "state": "Andhra Pradesh", "zip": "522 001", "country": "India", "geoPoint": {"lat": 16.29974, "lon": 80.45729}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500 058", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Vijayawada", "state": "Andhra Pradesh", "zip": "520008", "country": "India", "geoPoint": {"lat": 16.50745, "lon": 80.6466}}, {"facility": "Novartis Investigative Site", "city": "Vishakhapatnam", "state": "Andhra Pradesh", "zip": "530002", "country": "India"}, {"facility": "Novartis Investigative Site", "city": "Patna", "state": "Bihar", "zip": "800014", "country": "India", "geoPoint": {"lat": 25.59408, "lon": 85.13563}}, {"facility": "Novartis Investigative Site", "city": "Dehli", "state": "Delhi", "zip": "110063", "country": "India"}, {"facility": "Novartis Investigative Site", "city": "New Delhi", "state": "Delhi", "zip": "110 060", "country": "India", "geoPoint": {"lat": 28.63576, "lon": 77.22445}}, {"facility": "Novartis Investigative Site", "city": "Ahmedabad", "state": "Gujarat", "zip": "380 060", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "Novartis Investigative Site", "city": "Ahmedabad", "state": "Gujarat", "zip": "380016", "country": "India", "geoPoint": {"lat": 23.02579, "lon": 72.58727}}, {"facility": "Novartis Investigative Site", "city": "Gurgaon", "state": "Haryana", "zip": "122 002", "country": "India", "geoPoint": {"lat": 28.4601, "lon": 77.02635}}, {"facility": "Novartis Investigative Site", "city": "Bangalore", "state": "Karnataka", "zip": "560060", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Novartis Investigative Site", "city": "Hubli", "state": "Karnataka", "zip": "580022", "country": "India", "geoPoint": {"lat": 15.34776, "lon": 75.13378}}, {"facility": "Novartis Investigative Site", "city": "Mangalore", "state": "Karnataka", "zip": "575001", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Novartis Investigative Site", "city": "Mysore", "state": "Karnataka", "zip": "570001", "country": "India", "geoPoint": {"lat": 12.29791, "lon": 76.63925}}, {"facility": "Novartis Investigative Site", "city": "Cherthala", "state": "Kerala", "zip": "688524", "country": "India", "geoPoint": {"lat": 9.68444, "lon": 76.33558}}, {"facility": "Novartis Investigative Site", "city": "Kochi", "state": "Kerala", "zip": "683 594", "country": "India", "geoPoint": {"lat": 9.93988, "lon": 76.26022}}, {"facility": "Novartis Investigative Site", "city": "Kozhikode", "state": "Kerala", "zip": "673008", "country": "India", "geoPoint": {"lat": 11.24802, "lon": 75.7804}}, {"facility": "Novartis Investigative Site", "city": "Mumbai", "state": "Maharashtra", "zip": "401107", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "440010", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "440019", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Pune", "state": "Maharashtra", "zip": "411007", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Novartis Investigative Site", "city": "Pune", "state": "Maharashtra", "zip": "411014", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Novartis Investigative Site", "city": "Nashik", "state": "Maharastra", "zip": "422007", "country": "India", "geoPoint": {"lat": 19.99727, "lon": 73.79096}}, {"facility": "Novartis Investigative Site", "city": "Mohali", "state": "Punjab", "zip": "160 062", "country": "India", "geoPoint": {"lat": 30.67995, "lon": 76.72211}}, {"facility": "Novartis Investigative Site", "city": "Bikaner", "state": "Rajasthan", "zip": "334003", "country": "India", "geoPoint": {"lat": 28.01762, "lon": 73.31495}}, {"facility": "Novartis Investigative Site", "city": "Jaipur", "state": "Rajasthan", "zip": "302013", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Novartis Investigative Site", "city": "Jaipur", "state": "Rajasthan", "zip": "302020", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Novartis Investigative Site", "city": "Jaipur", "state": "Rajasthan", "zip": "302023", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Novartis Investigative Site", "city": "Coimbatore", "state": "Tamil Nadu", "zip": "641 045", "country": "India", "geoPoint": {"lat": 11.00555, "lon": 76.96612}}, {"facility": "Novartis Investigative Site", "city": "Vellore", "state": "Tamil Nadu", "zip": "632 004", "country": "India", "geoPoint": {"lat": 12.9184, "lon": 79.13255}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Telangana", "zip": "500 038", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Telangana", "zip": "500004", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Kanpur", "state": "Uttar Pradesh", "zip": "208 002", "country": "India", "geoPoint": {"lat": 26.46523, "lon": 80.34975}}, {"facility": "Novartis Investigative Site", "city": "DehraDun", "state": "Uttarakhand", "zip": "248001", "country": "India", "geoPoint": {"lat": 30.32295, "lon": 78.03168}}, {"facility": "Novartis Investigative Site", "city": "Kolkata", "state": "West Bengal", "zip": "700 107", "country": "India", "geoPoint": {"lat": 22.56263, "lon": 88.36304}}, {"facility": "Novartis Investigative Site", "city": "Wilton", "state": "Cork", "country": "Ireland"}, {"facility": "Novartis Investigative Site", "city": "Dublin", "zip": "24", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Novartis Investigative Site", "city": "Ashkelon", "zip": "78278", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"facility": "Novartis Investigative Site", "city": "Beer-Sheva", "zip": "8457108", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "zip": "91031", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigative Site", "city": "Kfar Saba", "zip": "4428164", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Novartis Investigative Site", "city": "Petach Tikva", "zip": "49100", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Novartis Investigative Site", "city": "Rehovot", "zip": "7610001", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Novartis Investigative Site", "city": "Tel Giborim, Holon", "zip": "58100", "country": "Israel"}, {"facility": "Novartis Investigative Site", "city": "Bari", "state": "BA", "zip": "70124", "country": "Italy", "geoPoint": {"lat": 41.11148, "lon": 16.8554}}, {"facility": "Novartis Investigative Site", "city": "Catania", "state": "CT", "zip": "95125", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Novartis Investigative Site", "city": "Catanzaro", "state": "CZ", "zip": "88100", "country": "Italy", "geoPoint": {"lat": 38.88247, "lon": 16.60086}}, {"facility": "Novartis Investigative Site", "city": "Firenze", "state": "FI", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Novartis Investigative Site", "city": "Messina", "state": "ME", "zip": "98125", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Novartis Investigative Site", "city": "Negrar", "state": "VR", "zip": "37024", "country": "Italy", "geoPoint": {"lat": 45.52918, "lon": 10.93899}}, {"facility": "Novartis Investigative Site", "city": "Ancona", "zip": "60127", "country": "Italy", "geoPoint": {"lat": 43.5942, "lon": 13.50337}}, {"facility": "Novartis Investigative Site", "city": "Messina", "zip": "98125", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Novartis Investigative Site", "city": "Pordenone", "zip": "33170", "country": "Italy", "geoPoint": {"lat": 45.95689, "lon": 12.66051}}, {"facility": "Novartis Investigative Site", "city": "Roma", "zip": "00168", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Novartis Investigative Site", "city": "Kasuga-city", "state": "Fukuoka", "zip": "816-0813", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Obihiro-city", "state": "Hokkaido", "zip": "080-0013", "country": "Japan", "geoPoint": {"lat": 42.91722, "lon": 143.20444}}, {"facility": "Novartis Investigative Site", "city": "Tomakomai-city", "state": "Hokkaido", "zip": "053-8506", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Novartis Investigative Site", "city": "Himeji-city", "state": "Hyogo", "zip": "672-8064", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Novartis Investigative Site", "city": "Naka-gun", "state": "Ibaraki", "zip": "319-1113", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Novartis Investigative Site", "city": "Kawasaki-city", "state": "Kanagawa", "zip": "215-0021", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "223-0059", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "231-8682", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "236 0051", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Yokohama", "state": "Kanagawa", "zip": "232-0064", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Yokkaichi-city", "state": "Mie", "zip": "510-8561", "country": "Japan", "geoPoint": {"lat": 34.96667, "lon": 136.61667}}, {"facility": "Novartis Investigative Site", "city": "Sendai-city", "state": "Miyagi", "zip": "980-0871", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Novartis Investigative Site", "city": "Kurashiki-city", "state": "Okayama", "zip": "712-8064", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Novartis Investigative Site", "city": "Okayama-city", "state": "Okayama", "zip": "702-8055", "country": "Japan", "geoPoint": {"lat": 34.65, "lon": 133.93333}}, {"facility": "Novartis Investigative Site", "city": "Kishiwada-city", "state": "Osaka", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Novartis Investigative Site", "city": "Tokyo", "state": "Shibuya Ku", "zip": "150 0013", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Novartis Investigative Site", "city": "Hamamatsu-city", "state": "Shizuoka", "zip": "431-3192", "country": "Japan", "geoPoint": {"lat": 34.7, "lon": 137.73333}}, {"facility": "Novartis Investigative Site", "city": "Chuo ku", "state": "Tokyo", "zip": "104-0031", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novartis Investigative Site", "city": "Itabashi-ku", "state": "Tokyo", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Novartis Investigative Site", "city": "Kokubunji-city", "state": "Tokyo", "zip": "185-0014", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Novartis Investigative Site", "city": "Ota-ku", "state": "Tokyo", "zip": "145 0063", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Novartis Investigative Site", "city": "Shinagawa-ku", "state": "Tokyo", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Novartis Investigative Site", "city": "Toshima ku", "state": "Tokyo", "zip": "170 0003", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Amman", "state": "JOR", "zip": "11152", "country": "Jordan", "geoPoint": {"lat": 31.95522, "lon": 35.94503}}, {"facility": "Novartis Investigative Site", "city": "Amman", "state": "JOR", "zip": "11183", "country": "Jordan", "geoPoint": {"lat": 31.95522, "lon": 35.94503}}, {"facility": "Novartis Investigative Site", "city": "Balvi", "state": "LVA", "zip": "4501", "country": "Latvia", "geoPoint": {"lat": 57.1313, "lon": 27.26583}}, {"facility": "Novartis Investigative Site", "city": "Bauska", "state": "LVA", "zip": "LV-3901", "country": "Latvia", "geoPoint": {"lat": 56.40794, "lon": 24.19439}}, {"facility": "Novartis Investigative Site", "city": "Daugavpils", "state": "LVA", "zip": "LV-5417", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "Novartis Investigative Site", "city": "Jurmala", "state": "LVA", "zip": "LV-2015", "country": "Latvia", "geoPoint": {"lat": 56.968, "lon": 23.77038}}, {"facility": "Novartis Investigative Site", "city": "Rezekne", "state": "LVA", "zip": "LV-4600", "country": "Latvia", "geoPoint": {"lat": 56.51025, "lon": 27.33994}}, {"facility": "Novartis Investigative Site", "city": "Riga", "state": "LVA", "zip": "1021", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Riga", "state": "LV", "zip": "1011", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Riga", "state": "LV", "zip": "LV-1038", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Daugavpils", "zip": "LV-5401", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "Novartis Investigative Site", "city": "Riga", "zip": "LV 1002", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "El Chouf", "state": "LBN", "zip": "1503201002", "country": "Lebanon"}, {"facility": "Novartis Investigative Site", "city": "Ashrafieh", "zip": "166830", "country": "Lebanon"}, {"facility": "Novartis Investigative Site", "city": "Beirut", "zip": "1107 2020", "country": "Lebanon", "geoPoint": {"lat": 33.88894, "lon": 35.49442}}, {"facility": "Novartis Investigative Site", "city": "Beirut", "zip": "166378", "country": "Lebanon", "geoPoint": {"lat": 33.88894, "lon": 35.49442}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "state": "LTU", "zip": "LT-04129", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "state": "LT", "zip": "LT-50128", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "state": "LT", "zip": "01117", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "zip": "LT-44320", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "zip": "LT-45130", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "zip": "LT-49449", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "zip": "LT-50154", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Klaipeda", "zip": "LT-92231", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"facility": "Novartis Investigative Site", "city": "Klaipeda", "zip": "LT-92288", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"facility": "Novartis Investigative Site", "city": "Siauliai", "zip": "LT-76231", "country": "Lithuania", "geoPoint": {"lat": 55.93333, "lon": 23.31667}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "zip": "06122", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44130", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44160", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Zapopan", "state": "Jalisco", "zip": "45200", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Novartis Investigative Site", "city": "Culiacan", "state": "MEX", "zip": "80020", "country": "Mexico", "geoPoint": {"lat": 24.79032, "lon": -107.38782}}, {"facility": "Novartis Investigative Site", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Novartis Investigative Site", "city": "Oaxaca", "zip": "68000", "country": "Mexico", "geoPoint": {"lat": 17.06542, "lon": -96.72365}}, {"facility": "Novartis Investigative Site", "city": "Veracruz", "zip": "91700", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Novartis Investigative Site", "city": "Breda", "state": "CK", "zip": "4818", "country": "Netherlands", "geoPoint": {"lat": 51.58656, "lon": 4.77596}}, {"facility": "Novartis Investigative Site", "city": "Eindhoven", "zip": "5623 EJ", "country": "Netherlands", "geoPoint": {"lat": 51.44083, "lon": 5.47778}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "zip": "9713 GZ", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Harderwijk", "zip": "3840 AC", "country": "Netherlands", "geoPoint": {"lat": 52.34167, "lon": 5.62083}}, {"facility": "Novartis Investigative Site", "city": "Heerlen", "zip": "6419 PC", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}, {"facility": "Novartis Investigative Site", "city": "Helmond", "zip": "5707 HA", "country": "Netherlands", "geoPoint": {"lat": 51.48167, "lon": 5.66111}}, {"facility": "Novartis Investigative Site", "city": "Hengelo", "zip": "7555 DL", "country": "Netherlands", "geoPoint": {"lat": 52.26583, "lon": 6.79306}}, {"facility": "Novartis Investigative Site", "city": "Rotterdam", "zip": "3045 PM", "country": "Netherlands", "geoPoint": {"lat": 51.9225, "lon": 4.47917}}, {"facility": "Novartis Investigative Site", "city": "Zutphen", "zip": "7207 AE", "country": "Netherlands", "geoPoint": {"lat": 52.13833, "lon": 6.20139}}, {"facility": "Novartis Investigative Site", "city": "Cercado De Lima", "state": "Lima", "zip": "01", "country": "Peru"}, {"facility": "Novartis Investigative Site", "city": "San Borja", "state": "Lima", "zip": "41", "country": "Peru", "geoPoint": {"lat": -12.09841, "lon": -77.01107}}, {"facility": "Novartis Investigative Site", "city": "San Isidro", "state": "Lima", "zip": "27", "country": "Peru", "geoPoint": {"lat": -12.11667, "lon": -77.05}}, {"facility": "Novartis Investigative Site", "city": "San Miguel", "state": "Lima", "zip": "32", "country": "Peru", "geoPoint": {"lat": -13.0125, "lon": -73.98083}}, {"facility": "Novartis Investigative Site", "city": "Lima", "zip": "14", "country": "Peru", "geoPoint": {"lat": -12.04318, "lon": -77.02824}}, {"facility": "Novartis Investigative Site", "city": "Lipa City", "state": "Batangas", "zip": "4217", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "Novartis Investigative Site", "city": "Manila", "state": "Metro Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Bulacan", "zip": "3020", "country": "Philippines", "geoPoint": {"lat": 14.79278, "lon": 120.87889}}, {"facility": "Novartis Investigative Site", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1102", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Ksawerow", "state": "POL", "zip": "95-054", "country": "Poland", "geoPoint": {"lat": 51.68288, "lon": 19.4028}}, {"facility": "Novartis Investigative Site", "city": "Wejherowo", "state": "POL", "zip": "84-200", "country": "Poland", "geoPoint": {"lat": 54.60568, "lon": 18.23559}}, {"facility": "Novartis Investigative Site", "city": "Aleksandrow Odzki", "zip": "95-070", "country": "Poland"}, {"facility": "Novartis Investigative Site", "city": "Bielsko-Biala", "zip": "43-300", "country": "Poland", "geoPoint": {"lat": 49.82245, "lon": 19.04686}}, {"facility": "Novartis Investigative Site", "city": "Elblag", "zip": "82-300", "country": "Poland", "geoPoint": {"lat": 54.1522, "lon": 19.40884}}, {"facility": "Novartis Investigative Site", "city": "Inowroclaw", "zip": "88-100", "country": "Poland", "geoPoint": {"lat": 52.79886, "lon": 18.26387}}, {"facility": "Novartis Investigative Site", "city": "Krakow", "zip": "30033", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Novartis Investigative Site", "city": "Krakow", "zip": "31159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Novartis Investigative Site", "city": "Lodz", "zip": "90-302", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Novartis Investigative Site", "city": "Ostrow Wielkopolski", "zip": "63-400", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Novartis Investigative Site", "city": "Sopot", "zip": "81-741", "country": "Poland", "geoPoint": {"lat": 54.4418, "lon": 18.56003}}, {"facility": "Novartis Investigative Site", "city": "Wroclaw", "zip": "50-445", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novartis Investigative Site", "city": "Zawadzkie", "zip": "47-120", "country": "Poland", "geoPoint": {"lat": 50.60503, "lon": 18.48467}}, {"facility": "Novartis Investigative Site", "city": "Coimbra", "zip": "3000-075", "country": "Portugal", "geoPoint": {"lat": 40.20564, "lon": -8.41955}}, {"facility": "Novartis Investigative Site", "city": "Coimbra", "zip": "3041-853", "country": "Portugal", "geoPoint": {"lat": 40.20564, "lon": -8.41955}}, {"facility": "Novartis Investigative Site", "city": "Lisboa", "zip": "1998-018", "country": "Portugal", "geoPoint": {"lat": 38.71667, "lon": -9.13333}}, {"facility": "Novartis Investigative Site", "city": "Porto", "zip": "4100-180", "country": "Portugal", "geoPoint": {"lat": 41.14961, "lon": -8.61099}}, {"facility": "Novartis Investigative Site", "city": "Craiova", "state": "ROM", "zip": "200712", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Novartis Investigative Site", "city": "Deva", "state": "ROM", "zip": "330084", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Novartis Investigative Site", "city": "Timisoara", "state": "Timis", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Novartis Investigative Site", "city": "Arad", "zip": "310085", "country": "Romania", "geoPoint": {"lat": 46.18333, "lon": 21.31667}}, {"facility": "Novartis Investigative Site", "city": "Bacau", "zip": "600252", "country": "Romania", "geoPoint": {"lat": 46.56718, "lon": 26.91384}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500086", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500283", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "zip": "030317", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Cluj Napoca", "zip": "400139", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Cluj Napoca", "zip": "400162", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Constanta", "zip": "900591", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"facility": "Novartis Investigative Site", "city": "Deva", "zip": "330162", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Novartis Investigative Site", "city": "Pitesti", "zip": "110084", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "Novartis Investigative Site", "city": "Barnaul", "zip": "656024", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "Novartis Investigative Site", "city": "Barnaul", "zip": "656045", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "Novartis Investigative Site", "city": "Barnaul", "zip": "656050", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "Novartis Investigative Site", "city": "Chelyabinsk", "zip": "454021", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "Novartis Investigative Site", "city": "Ivanovo", "zip": "153005", "country": "Russian Federation", "geoPoint": {"lat": 56.99719, "lon": 40.97139}}, {"facility": "Novartis Investigative Site", "city": "Kazan", "zip": "420012", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "Novartis Investigative Site", "city": "Kemerovo", "zip": "650002", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "105077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "121309", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "125993", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Nizhny Novgorod", "zip": "603011", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Novartis Investigative Site", "city": "Nizhny Novgorod", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Novartis Investigative Site", "city": "Novosibirsk", "zip": "630099", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Novartis Investigative Site", "city": "Novosibirsk", "zip": "630102", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Novartis Investigative Site", "city": "Omsk", "zip": "644112", "country": "Russian Federation", "geoPoint": {"lat": 54.99244, "lon": 73.36859}}, {"facility": "Novartis Investigative Site", "city": "Perm", "zip": "614056", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Novartis Investigative Site", "city": "Perm", "zip": "614068", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Novartis Investigative Site", "city": "Pskov", "zip": "180007", "country": "Russian Federation", "geoPoint": {"lat": 57.8136, "lon": 28.3496}}, {"facility": "Novartis Investigative Site", "city": "Pyatigorsk", "zip": "357500", "country": "Russian Federation", "geoPoint": {"lat": 44.04861, "lon": 43.05944}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "191123", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint Petersburg", "zip": "199106", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "191186", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "196143", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saratov", "zip": "410012", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Novartis Investigative Site", "city": "Sestroretsk", "zip": "197706", "country": "Russian Federation", "geoPoint": {"lat": 60.09801, "lon": 29.96378}}, {"facility": "Novartis Investigative Site", "city": "Smolensk", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Novartis Investigative Site", "city": "Smolensk", "zip": "214006", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Novartis Investigative Site", "city": "Smolensk", "zip": "214019", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Novartis Investigative Site", "city": "St Petersburg", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "St. Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Tomsk", "zip": "634063", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Novartis Investigative Site", "city": "Tver", "zip": "170036", "country": "Russian Federation", "geoPoint": {"lat": 56.85836, "lon": 35.90057}}, {"facility": "Novartis Investigative Site", "city": "Ufa", "zip": "450000", "country": "Russian Federation", "geoPoint": {"lat": 54.74306, "lon": 55.96779}}, {"facility": "Novartis Investigative Site", "city": "Ulyanovsk", "zip": "432063", "country": "Russian Federation", "geoPoint": {"lat": 54.32824, "lon": 48.38657}}, {"facility": "Novartis Investigative Site", "city": "Vladikavkaz", "zip": "362019", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Novartis Investigative Site", "city": "Volgograd", "zip": "400120", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Novartis Investigative Site", "city": "Vsevolozhsk", "zip": "188640", "country": "Russian Federation", "geoPoint": {"lat": 60.01512, "lon": 30.67314}}, {"facility": "Novartis Investigative Site", "city": "Yaroslavl", "zip": "150002", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Novartis Investigative Site", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Novartis Investigative Site", "city": "Kosice", "state": "Slovak Republic", "zip": "040 01", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigative Site", "city": "Kosice", "state": "Slovak Republic", "zip": "04001", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigative Site", "city": "Kezmarok", "zip": "060 01", "country": "Slovakia", "geoPoint": {"lat": 49.13571, "lon": 20.43352}}, {"facility": "Novartis Investigative Site", "city": "Kosice", "zip": "04001", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"facility": "Novartis Investigative Site", "city": "Liptovsky Mikulas", "zip": "031 23", "country": "Slovakia", "geoPoint": {"lat": 49.08061, "lon": 19.62218}}, {"facility": "Novartis Investigative Site", "city": "Poprad", "zip": "058 01", "country": "Slovakia", "geoPoint": {"lat": 49.06144, "lon": 20.29798}}, {"facility": "Novartis Investigative Site", "city": "Presov", "zip": "080 01", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Novartis Investigative Site", "city": "Spisska Nova Ves", "zip": "052 01", "country": "Slovakia", "geoPoint": {"lat": 48.94464, "lon": 20.56153}}, {"facility": "Novartis Investigative Site", "city": "Trencin", "zip": "91101", "country": "Slovakia", "geoPoint": {"lat": 48.89452, "lon": 18.04436}}, {"facility": "Novartis Investigative Site", "city": "Zilina", "zip": "01207", "country": "Slovakia", "geoPoint": {"lat": 49.22315, "lon": 18.73941}}, {"facility": "Novartis Investigative Site", "city": "Zvolen", "zip": "960 01", "country": "Slovakia", "geoPoint": {"lat": 48.57442, "lon": 19.15324}}, {"facility": "Novartis Investigative Site", "city": "Berea", "state": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.85185, "lon": 30.99337}}, {"facility": "Novartis Investigative Site", "city": "Durban", "state": "Kwazulu Natal", "zip": "4093", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Novartis Investigative Site", "city": "Kempton Park", "state": "ZAF", "zip": "1619", "country": "South Africa", "geoPoint": {"lat": -26.10859, "lon": 28.2377}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7531", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigative Site", "city": "Malaga", "state": "Andalucia", "zip": "29010", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Novartis Investigative Site", "city": "Marbella", "state": "Andalucia", "zip": "29603", "country": "Spain", "geoPoint": {"lat": 36.51543, "lon": -4.88583}}, {"facility": "Novartis Investigative Site", "city": "Esparraguera", "state": "Barcelona", "zip": "08292", "country": "Spain", "geoPoint": {"lat": 41.53809, "lon": 1.87025}}, {"facility": "Novartis Investigative Site", "city": "Laredo", "state": "Cantabria", "zip": "39770", "country": "Spain", "geoPoint": {"lat": 43.4098, "lon": -3.41613}}, {"facility": "Novartis Investigative Site", "city": "Vila-real", "state": "Castellon", "zip": "12540", "country": "Spain", "geoPoint": {"lat": 39.9383, "lon": -0.10087}}, {"facility": "Novartis Investigative Site", "city": "Girona", "state": "Catalunya", "zip": "17007", "country": "Spain", "geoPoint": {"lat": 41.98311, "lon": 2.82493}}, {"facility": "Novartis Investigative Site", "city": "Alzira", "state": "Comunidad Valenciana", "zip": "46600", "country": "Spain", "geoPoint": {"lat": 39.15, "lon": -0.43333}}, {"facility": "Novartis Investigative Site", "city": "Valencia", "state": "Comunidad Valenciana", "zip": "46015", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novartis Investigative Site", "city": "Caceres", "state": "Extremadura", "zip": "10003", "country": "Spain", "geoPoint": {"lat": 39.47649, "lon": -6.37224}}, {"facility": "Novartis Investigative Site", "city": "La Laguna", "state": "Santa Cruz De Tenerife", "zip": "38320", "country": "Spain", "geoPoint": {"lat": 28.4853, "lon": -16.32014}}, {"facility": "Novartis Investigative Site", "city": "Leon", "zip": "24071", "country": "Spain", "geoPoint": {"lat": 42.60003, "lon": -5.57032}}, {"facility": "Novartis Investigative Site", "city": "Zaragoza", "zip": "50015", "country": "Spain", "geoPoint": {"lat": 41.65606, "lon": -0.87734}}, {"facility": "Novartis Investigative Site", "city": "Lidingo", "zip": "181 58", "country": "Sweden", "geoPoint": {"lat": 59.36667, "lon": 18.13333}}, {"facility": "Novartis Investigative Site", "city": "Stockholm", "zip": "111 57", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Novartis Investigative Site", "city": "Gossau", "zip": "9200", "country": "Switzerland", "geoPoint": {"lat": 47.41551, "lon": 9.25482}}, {"facility": "Novartis Investigative Site", "city": "Muang", "state": "Nonthaburi", "zip": "11000", "country": "Thailand"}, {"facility": "Novartis Investigative Site", "city": "Khon Kaen", "state": "THA", "zip": "40002", "country": "Thailand", "geoPoint": {"lat": 16.44671, "lon": 102.833}}, {"facility": "Novartis Investigative Site", "city": "Bangkok", "zip": "10400", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Novartis Investigative Site", "city": "Bangkok", "zip": "26120", "country": "Thailand", "geoPoint": {"lat": 13.75398, "lon": 100.50144}}, {"facility": "Novartis Investigative Site", "city": "Chiang Mai", "zip": "50200", "country": "Thailand", "geoPoint": {"lat": 18.79038, "lon": 98.98468}}, {"facility": "Novartis Investigative Site", "city": "East Yorkshire", "zip": "HU16 5JQ", "country": "United Kingdom"}, {"facility": "Novartis Investigative Site", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigative Site", "city": "Wiltshire", "zip": "SN15 2SB", "country": "United Kingdom"}, {"facility": "Novartis Investigative Site", "city": "Ho Chi Minh", "state": "VNM", "zip": "700000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}, {"facility": "Novartis Investigative Site", "city": "Hanoi", "zip": "100000", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"facility": "Novartis Investigative Site", "city": "Ho Chi Minh", "zip": "700000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}, "referencesModule": {"references": [{"pmid": "34452934", "type": "DERIVED", "citation": "Chapman K, van Zyl-Smit R, Maspero J, Kerstjens HAM, Gon Y, Hosoe M, Tanase AM, Pethe A, Shu X, D'Andrea P. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. BMJ Open Respir Res. 2021 Aug;8(1):e000819. doi: 10.1136/bmjresp-2020-000819."}, {"pmid": "32653074", "type": "DERIVED", "citation": "Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "4851 participants were screened of which 3092 participants were randomized to 1 of the 5 treatment groups with a randomization ratio of 1:1:1:1:1.", "recruitmentDetails": "Participants took part in 415 investigative sites in 41 countries", "groups": [{"id": "FG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "FG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "FG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "FG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "FG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "All patients who were assigned a randomization number", "achievements": [{"groupId": "FG000", "numSubjects": "619"}, {"groupId": "FG001", "numSubjects": "620"}, {"groupId": "FG002", "numSubjects": "618"}, {"groupId": "FG003", "numSubjects": "617"}, {"groupId": "FG004", "numSubjects": "618"}]}, {"type": "Full Analysis Set (FAS)", "comment": "All patients in the randomization set who received at least one dose of study medication", "achievements": [{"groupId": "FG000", "numSubjects": "615"}, {"groupId": "FG001", "numSubjects": "616"}, {"groupId": "FG002", "numSubjects": "611"}, {"groupId": "FG003", "numSubjects": "607"}, {"groupId": "FG004", "numSubjects": "612"}]}, {"type": "Safety Set (SAF)", "comment": "All patients who received at least one dose of study medication whether or not being randomized", "achievements": [{"groupId": "FG000", "numSubjects": "616"}, {"groupId": "FG001", "numSubjects": "617"}, {"groupId": "FG002", "numSubjects": "613"}, {"groupId": "FG003", "numSubjects": "608"}, {"groupId": "FG004", "numSubjects": "618"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "580"}, {"groupId": "FG001", "numSubjects": "582"}, {"groupId": "FG002", "numSubjects": "577"}, {"groupId": "FG003", "numSubjects": "580"}, {"groupId": "FG004", "numSubjects": "582"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "38"}, {"groupId": "FG002", "numSubjects": "41"}, {"groupId": "FG003", "numSubjects": "37"}, {"groupId": "FG004", "numSubjects": "36"}]}], "dropWithdraws": [{"type": "Subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "26"}, {"groupId": "FG003", "numSubjects": "25"}, {"groupId": "FG004", "numSubjects": "27"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "8"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "4"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized Set (RAN) consisted of all participants who were assigned a randomization number, regardless of whether or not they actually received study medication.", "groups": [{"id": "BG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "BG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "BG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "BG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "BG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "619"}, {"groupId": "BG001", "value": "620"}, {"groupId": "BG002", "value": "618"}, {"groupId": "BG003", "value": "617"}, {"groupId": "BG004", "value": "618"}, {"groupId": "BG005", "value": "3092"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.1", "spread": "12.91"}, {"groupId": "BG001", "value": "52.4", "spread": "12.71"}, {"groupId": "BG002", "value": "52.0", "spread": "12.81"}, {"groupId": "BG003", "value": "51.8", "spread": "12.86"}, {"groupId": "BG004", "value": "52.9", "spread": "12.23"}, {"groupId": "BG005", "value": "52.2", "spread": "12.70"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "381"}, {"groupId": "BG001", "value": "362"}, {"groupId": "BG002", "value": "380"}, {"groupId": "BG003", "value": "378"}, {"groupId": "BG004", "value": "417"}, {"groupId": "BG005", "value": "1918"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "238"}, {"groupId": "BG001", "value": "258"}, {"groupId": "BG002", "value": "238"}, {"groupId": "BG003", "value": "239"}, {"groupId": "BG004", "value": "201"}, {"groupId": "BG005", "value": "1174"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Caucasian", "measurements": [{"groupId": "BG000", "value": "456"}, {"groupId": "BG001", "value": "458"}, {"groupId": "BG002", "value": "453"}, {"groupId": "BG003", "value": "452"}, {"groupId": "BG004", "value": "468"}, {"groupId": "BG005", "value": "2287"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "17"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "139"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "133"}, {"groupId": "BG003", "value": "135"}, {"groupId": "BG004", "value": "131"}, {"groupId": "BG005", "value": "671"}]}, {"title": "Native American", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "32"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "21"}, {"groupId": "BG004", "value": "13"}, {"groupId": "BG005", "value": "84"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.\n\nThe primary endpoint considered the following 2 comparison groups:\n\n* QVM149 150/50/80 \u03bcg o.d. compared with QMF149 150/160 \u03bcg o.d. both delivered via Concept1\n* QVM149 150/50/160 \u03bcg o.d. compared with QMF149 150/320 \u03bcg o.d. both delivered via Concept1.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litre (L)", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "606"}, {"groupId": "OG003", "value": "602"}, {"groupId": "OG004", "value": "607"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.050", "spread": "0.0128"}, {"groupId": "OG001", "value": "2.029", "spread": "0.0129"}, {"groupId": "OG002", "value": "1.984", "spread": "0.0129"}, {"groupId": "OG003", "value": "1.953", "spread": "0.0130"}, {"groupId": "OG004", "value": "1.930", "spread": "0.0131"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Mixed Model for Repeated Measures (MMRM)", "paramType": "LS Mean", "paramValue": "0.065", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.031", "ciUpperLimit": "0.099", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0176"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.076", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.041", "ciUpperLimit": "0.111", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0176"}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52", "description": "The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means \\> 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means \\< 50% of predicted FEV1). The ACQ-7 total score reported below was calculated as the mean of scores of all 7 items and ranged between 0 and 6, with higher scores indicating worse asthma symptom control.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "607"}, {"groupId": "OG001", "value": "595"}, {"groupId": "OG002", "value": "596"}, {"groupId": "OG003", "value": "598"}, {"groupId": "OG004", "value": "599"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "566"}, {"groupId": "OG001", "value": "559"}, {"groupId": "OG002", "value": "562"}, {"groupId": "OG003", "value": "559"}, {"groupId": "OG004", "value": "562"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.542", "spread": "0.0329"}, {"groupId": "OG001", "value": "1.543", "spread": "0.0330"}, {"groupId": "OG002", "value": "1.528", "spread": "0.0329"}, {"groupId": "OG003", "value": "1.614", "spread": "0.0331"}, {"groupId": "OG004", "value": "1.628", "spread": "0.0329"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "552"}, {"groupId": "OG001", "value": "537"}, {"groupId": "OG002", "value": "547"}, {"groupId": "OG003", "value": "536"}, {"groupId": "OG004", "value": "547"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.406", "spread": "0.0334"}, {"groupId": "OG001", "value": "1.535", "spread": "0.0337"}, {"groupId": "OG002", "value": "1.465", "spread": "0.0335"}, {"groupId": "OG003", "value": "1.545", "spread": "0.0338"}, {"groupId": "OG004", "value": "1.527", "spread": "0.0335"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.729", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.014", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.066", "ciUpperLimit": "0.094", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0406"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.034", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.086", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.165", "ciUpperLimit": "-0.006", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0404"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.085", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.071", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.151", "ciUpperLimit": "0.010", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0409"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.038", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.084", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.164", "ciUpperLimit": "-0.005", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0406"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.157", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.059", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.140", "ciUpperLimit": "0.023", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0415"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.003", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.121", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.202", "ciUpperLimit": "-0.040", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0414"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.814", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.010", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.092", "ciUpperLimit": "0.072", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0420"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.845", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.008", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.073", "ciUpperLimit": "0.090", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0416"}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.\n\nThis secondary endpoint considered the following 2 comparison groups:\n\n* QVM149 150/50/80 \u03bcg o.d. via Concept1 compared with salmeterol/fluticasone 50/500 \u03bcg b.i.d. via Accuhaler\u00ae\n* QVM149 150/50/160 \u03bcg o.d. via Concept 1 compared with salmeterol/fluticasone 50/500 \u03bcg b.i.d. via Accuhaler\u00ae", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litre (L)", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "606"}, {"groupId": "OG003", "value": "602"}, {"groupId": "OG004", "value": "607"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.050", "spread": "0.0128"}, {"groupId": "OG001", "value": "2.029", "spread": "0.0129"}, {"groupId": "OG002", "value": "1.984", "spread": "0.0129"}, {"groupId": "OG003", "value": "1.953", "spread": "0.0130"}, {"groupId": "OG004", "value": "1.930", "spread": "0.0131"}]}]}], "analyses": [{"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.119", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.085", "ciUpperLimit": "0.154", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0177"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.099", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.064", "ciUpperLimit": "0.133", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0177"}]}, {"type": "SECONDARY", "title": "Trough FEV1 at Week 52", "description": "Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litre (L)", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "606"}, {"groupId": "OG003", "value": "602"}, {"groupId": "OG004", "value": "607"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.050", "spread": "0.0129"}, {"groupId": "OG001", "value": "1.992", "spread": "0.0130"}, {"groupId": "OG002", "value": "1.965", "spread": "0.0130"}, {"groupId": "OG003", "value": "1.930", "spread": "0.0130"}, {"groupId": "OG004", "value": "1.905", "spread": "0.0132"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.086", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.051", "ciUpperLimit": "0.120", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0176"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.145", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.111", "ciUpperLimit": "0.180", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0178"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.062", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.027", "ciUpperLimit": "0.096", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0178"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.052", "ciUpperLimit": "0.122", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0179"}]}, {"type": "SECONDARY", "title": "Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12", "description": "Pre-dose FVC is defined as average of the two FVC measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FVC is the total amount of air exhaled during the FEV test.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "litre (L)", "timeFrame": "4 weeks, 12 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "606"}, {"groupId": "OG001", "value": "594"}, {"groupId": "OG002", "value": "592"}, {"groupId": "OG003", "value": "596"}, {"groupId": "OG004", "value": "598"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}, {"groupId": "OG001", "value": "573"}, {"groupId": "OG002", "value": "573"}, {"groupId": "OG003", "value": "579"}, {"groupId": "OG004", "value": "577"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.091", "spread": "0.0161"}, {"groupId": "OG001", "value": "3.059", "spread": "0.0163"}, {"groupId": "OG002", "value": "3.018", "spread": "0.0163"}, {"groupId": "OG003", "value": "3.020", "spread": "0.0163"}, {"groupId": "OG004", "value": "2.952", "spread": "0.0163"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "580"}, {"groupId": "OG001", "value": "569"}, {"groupId": "OG002", "value": "573"}, {"groupId": "OG003", "value": "562"}, {"groupId": "OG004", "value": "568"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.067", "spread": "0.0162"}, {"groupId": "OG001", "value": "3.065", "spread": "0.0164"}, {"groupId": "OG002", "value": "3.011", "spread": "0.0163"}, {"groupId": "OG003", "value": "3.014", "spread": "0.0164"}, {"groupId": "OG004", "value": "2.965", "spread": "0.0163"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.073", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.030", "ciUpperLimit": "0.116", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0218"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.139", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.096", "ciUpperLimit": "0.181", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0217"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.074", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.039", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.004", "ciUpperLimit": "0.082", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0220"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.108", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.065", "ciUpperLimit": "0.150", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0219"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.010", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.056", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.014", "ciUpperLimit": "0.099", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0219"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.102", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.059", "ciUpperLimit": "0.145", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0218"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.022", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.007", "ciUpperLimit": "0.094", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0221"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.099", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.056", "ciUpperLimit": "0.142", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0220"}]}, {"type": "SECONDARY", "title": "Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks", "description": "FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/s", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "606"}, {"groupId": "OG003", "value": "602"}, {"groupId": "OG004", "value": "607"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.354", "spread": "0.0190"}, {"groupId": "OG001", "value": "1.263", "spread": "0.0192"}, {"groupId": "OG002", "value": "1.260", "spread": "0.0191"}, {"groupId": "OG003", "value": "1.214", "spread": "0.0192"}, {"groupId": "OG004", "value": "1.207", "spread": "0.0194"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.095", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.045", "ciUpperLimit": "0.145", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0254"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.147", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.097", "ciUpperLimit": "0.198", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0256"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.057", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.049", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.001", "ciUpperLimit": "0.099", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0256"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.029", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.056", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.006", "ciUpperLimit": "0.107", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0258"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment", "description": "PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose) at home. At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline, 26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "596"}, {"groupId": "OG001", "value": "584"}, {"groupId": "OG002", "value": "581"}, {"groupId": "OG003", "value": "584"}, {"groupId": "OG004", "value": "586"}]}], "classes": [{"title": "Week 26 - Mean morning PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "596"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "581"}, {"groupId": "OG003", "value": "584"}, {"groupId": "OG004", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "47.7", "spread": "1.93"}, {"groupId": "OG001", "value": "40.5", "spread": "1.95"}, {"groupId": "OG002", "value": "29.5", "spread": "1.95"}, {"groupId": "OG003", "value": "25.6", "spread": "1.95"}, {"groupId": "OG004", "value": "12.5", "spread": "1.95"}]}]}, {"title": "Week 26 - Mean evening PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "594"}, {"groupId": "OG001", "value": "584"}, {"groupId": "OG002", "value": "580"}, {"groupId": "OG003", "value": "578"}, {"groupId": "OG004", "value": "577"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.6", "spread": "1.87"}, {"groupId": "OG001", "value": "34.7", "spread": "1.88"}, {"groupId": "OG002", "value": "22.8", "spread": "1.88"}, {"groupId": "OG003", "value": "20.6", "spread": "1.89"}, {"groupId": "OG004", "value": "10.4", "spread": "1.89"}]}]}, {"title": "Week 52 - Mean morning PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "596"}, {"groupId": "OG001", "value": "584"}, {"groupId": "OG002", "value": "581"}, {"groupId": "OG003", "value": "583"}, {"groupId": "OG004", "value": "586"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "47.5", "spread": "2.03"}, {"groupId": "OG001", "value": "41.2", "spread": "2.05"}, {"groupId": "OG002", "value": "28.8", "spread": "2.05"}, {"groupId": "OG003", "value": "25.6", "spread": "2.06"}, {"groupId": "OG004", "value": "12.7", "spread": "2.05"}]}]}, {"title": "Week 52 - Mean evening PEF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "593"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "578"}, {"groupId": "OG003", "value": "576"}, {"groupId": "OG004", "value": "578"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "38.7", "spread": "1.97"}, {"groupId": "OG001", "value": "35.0", "spread": "1.99"}, {"groupId": "OG002", "value": "21.2", "spread": "1.99"}, {"groupId": "OG003", "value": "20.1", "spread": "2.00"}, {"groupId": "OG004", "value": "9.2", "spread": "1.99"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Linear Mixed Model (LMM)", "paramType": "LS Mean", "paramValue": "18.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.2", "ciUpperLimit": "23.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.59"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "35.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "30.2", "ciUpperLimit": "40.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.58"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "14.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.8", "ciUpperLimit": "20.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.61"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "28.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "22.9", "ciUpperLimit": "33.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.60"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "16.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "11.8", "ciUpperLimit": "21.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.53"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "29.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "24.2", "ciUpperLimit": "34.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.53"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "14.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.1", "ciUpperLimit": "19.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.55"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "24.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "19.3", "ciUpperLimit": "29.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.54"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "18.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.4", "ciUpperLimit": "24.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.72"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "34.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "29.5", "ciUpperLimit": "40.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.70"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "15.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.2", "ciUpperLimit": "20.9", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.74"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52 - Mean morning PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "28.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "23.2", "ciUpperLimit": "33.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.72"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "17.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "12.3", "ciUpperLimit": "22.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.66"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "29.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "24.2", "ciUpperLimit": "34.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.66"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "15.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.7", "ciUpperLimit": "20.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.69"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52 - Mean evening PEF", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "25.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.5", "ciUpperLimit": "31.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.68"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "566"}, {"groupId": "OG001", "value": "552"}, {"groupId": "OG002", "value": "559"}, {"groupId": "OG003", "value": "554"}, {"groupId": "OG004", "value": "558"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.4", "spread": "1.35"}, {"groupId": "OG001", "value": "18.0", "spread": "1.36"}, {"groupId": "OG002", "value": "22.2", "spread": "1.36"}, {"groupId": "OG003", "value": "18.0", "spread": "1.37"}, {"groupId": "OG004", "value": "18.9", "spread": "1.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.907", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.3", "ciUpperLimit": "3.8", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.81"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.055", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1", "ciUpperLimit": "7.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.81"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.997", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.6", "ciUpperLimit": "3.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.83"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.606", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.5", "ciUpperLimit": "2.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.82"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems).", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "594"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "579"}, {"groupId": "OG003", "value": "579"}, {"groupId": "OG004", "value": "578"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.5", "spread": "1.32"}, {"groupId": "OG001", "value": "17.9", "spread": "1.34"}, {"groupId": "OG002", "value": "21.8", "spread": "1.33"}, {"groupId": "OG003", "value": "18.0", "spread": "1.34"}, {"groupId": "OG004", "value": "18.8", "spread": "1.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.712", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.8", "ciUpperLimit": "4.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.038", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "7.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.943", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.7", "ciUpperLimit": "3.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.80"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.612", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.4", "ciUpperLimit": "2.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.79"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was \"How did you sleep last night?\" had to be answered with \"I did not wake up because of any breathing problems\" with scores from 0 (no problem)-4 (very severe problems).", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "599"}, {"groupId": "OG001", "value": "584"}, {"groupId": "OG002", "value": "582"}, {"groupId": "OG003", "value": "584"}, {"groupId": "OG004", "value": "586"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.0", "spread": "1.11"}, {"groupId": "OG001", "value": "17.6", "spread": "1.12"}, {"groupId": "OG002", "value": "18.4", "spread": "1.13"}, {"groupId": "OG003", "value": "16.1", "spread": "1.13"}, {"groupId": "OG004", "value": "16.9", "spread": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.809", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.3", "ciUpperLimit": "2.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.51"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.467", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.9", "ciUpperLimit": "4.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.50"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.318", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.5", "ciUpperLimit": "4.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.52"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.640", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "3.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.51"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks", "description": "All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was \"How did you sleep last night?\" had to be answered with \"I did not wake up because of any breathing problems\" with scores from 0 (no problem)-4 (very severe problems).", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "599"}, {"groupId": "OG001", "value": "584"}, {"groupId": "OG002", "value": "582"}, {"groupId": "OG003", "value": "584"}, {"groupId": "OG004", "value": "586"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.5", "spread": "1.33"}, {"groupId": "OG001", "value": "18.5", "spread": "1.35"}, {"groupId": "OG002", "value": "19.9", "spread": "1.35"}, {"groupId": "OG003", "value": "15.5", "spread": "1.35"}, {"groupId": "OG004", "value": "15.6", "spread": "1.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.814", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.0", "ciUpperLimit": "3.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.83"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.036", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.2", "ciUpperLimit": "7.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.83"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.098", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.6", "ciUpperLimit": "6.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.84"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.118", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.7", "ciUpperLimit": "6.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.84"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks", "description": "Percentage of days without rescue medication usage (100 \u03bcg salbutamol/90 \u03bcg albuterol via metered-dose inhaler) as recorded by e-diary over 26 and 52 weeks of treatment.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "590"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "578"}, {"groupId": "OG003", "value": "580"}, {"groupId": "OG004", "value": "579"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "590"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "578"}, {"groupId": "OG003", "value": "580"}, {"groupId": "OG004", "value": "579"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.5", "spread": "1.32"}, {"groupId": "OG001", "value": "19.5", "spread": "1.33"}, {"groupId": "OG002", "value": "23.3", "spread": "1.33"}, {"groupId": "OG003", "value": "18.2", "spread": "1.33"}, {"groupId": "OG004", "value": "19.6", "spread": "1.33"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "583"}, {"groupId": "OG001", "value": "574"}, {"groupId": "OG002", "value": "576"}, {"groupId": "OG003", "value": "576"}, {"groupId": "OG004", "value": "578"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.0", "spread": "1.36"}, {"groupId": "OG001", "value": "21.9", "spread": "1.36"}, {"groupId": "OG002", "value": "24.9", "spread": "1.36"}, {"groupId": "OG003", "value": "20.8", "spread": "1.37"}, {"groupId": "OG004", "value": "21.8", "spread": "1.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.645", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.2", "ciUpperLimit": "2.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.74"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.095", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5", "ciUpperLimit": "6.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.73"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.460", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.1", "ciUpperLimit": "4.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.75"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.971", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.5", "ciUpperLimit": "3.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.75"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.963", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.4", "ciUpperLimit": "3.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.075", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.3", "ciUpperLimit": "6.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.77"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.517", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "4.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.79"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.956", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.4", "ciUpperLimit": "3.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ \u2265 0.5 at Week 26 and Week 52", "description": "Change from baseline in ACQ-7 scores of \u2264 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means \\> 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means \\< 50% of predicted FEV1). The total score was calculated as the mean of all questions.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "566"}, {"groupId": "OG001", "value": "559"}, {"groupId": "OG002", "value": "562"}, {"groupId": "OG003", "value": "559"}, {"groupId": "OG004", "value": "562"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "71.2"}, {"groupId": "OG001", "value": "71.7"}, {"groupId": "OG002", "value": "74.2"}, {"groupId": "OG003", "value": "70.7"}, {"groupId": "OG004", "value": "67.4"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "552"}, {"groupId": "OG001", "value": "537"}, {"groupId": "OG002", "value": "547"}, {"groupId": "OG003", "value": "536"}, {"groupId": "OG004", "value": "547"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "78.8"}, {"groupId": "OG001", "value": "72.8"}, {"groupId": "OG002", "value": "77.9"}, {"groupId": "OG003", "value": "73.1"}, {"groupId": "OG004", "value": "72.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.535", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "0.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.70", "ciUpperLimit": "1.20"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.151", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.93", "ciUpperLimit": "1.57"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.380", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.86", "ciUpperLimit": "1.48"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.172", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.92", "ciUpperLimit": "1.57"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.510", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.83", "ciUpperLimit": "1.47"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.017", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.06", "ciUpperLimit": "1.86"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.744", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "1.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "1.38"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.922", "statisticalMethod": "Logistic regression model", "paramType": "Odds Ratio (OR)", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.29"}]}, {"type": "SECONDARY", "title": "Time to First Hospitalization for Asthma Exacerbation", "description": "Time from start of treatment until the first event (hospitalization for asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the hospitalization was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "52 weeks on average, up to 416 days", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "367.0", "lowerLimit": "2", "upperLimit": "416"}, {"groupId": "OG001", "value": "367.0", "lowerLimit": "2", "upperLimit": "396"}, {"groupId": "OG002", "value": "367.0", "lowerLimit": "1", "upperLimit": "411"}, {"groupId": "OG003", "value": "367.0", "lowerLimit": "1", "upperLimit": "408"}, {"groupId": "OG004", "value": "367.0", "lowerLimit": "1", "upperLimit": "416"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.371", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "1.63"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.996", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "2.66"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.145", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.89", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "4.47"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.150", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "4.43"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation by Exacerbation Category", "description": "Time from start of treatment until the first event (asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the start date of the exacerbation was considered to calculate the time to event (i.e., the number of days from start of treatment up to the event start date).\n\nThe exacerbation categories were: All (mild, moderate and severe), combination of moderate or severe and severe.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "52 weeks on average, up to 416 days", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"title": "Moderate or severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "366.0", "lowerLimit": "2", "upperLimit": "416"}, {"groupId": "OG001", "value": "366.0", "lowerLimit": "2", "upperLimit": "396"}, {"groupId": "OG002", "value": "366.0", "lowerLimit": "1", "upperLimit": "411"}, {"groupId": "OG003", "value": "365.0", "lowerLimit": "1", "upperLimit": "387"}, {"groupId": "OG004", "value": "365.0", "lowerLimit": "1", "upperLimit": "416"}]}]}, {"title": "Severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "366.0", "lowerLimit": "2", "upperLimit": "416"}, {"groupId": "OG001", "value": "366.0", "lowerLimit": "2", "upperLimit": "396"}, {"groupId": "OG002", "value": "366.0", "lowerLimit": "1", "upperLimit": "411"}, {"groupId": "OG003", "value": "366.0", "lowerLimit": "1", "upperLimit": "389"}, {"groupId": "OG004", "value": "366.0", "lowerLimit": "1", "upperLimit": "416"}]}]}, {"title": "All (mild, moderate or severe) asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "363.0", "lowerLimit": "2", "upperLimit": "416"}, {"groupId": "OG001", "value": "364.0", "lowerLimit": "2", "upperLimit": "396"}, {"groupId": "OG002", "value": "361.0", "lowerLimit": "1", "upperLimit": "411"}, {"groupId": "OG003", "value": "360.0", "lowerLimit": "1", "upperLimit": "384"}, {"groupId": "OG004", "value": "278.0", "lowerLimit": "1", "upperLimit": "416"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.523", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "1.15"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.58", "ciUpperLimit": "0.84"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.164", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.06"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.005", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "0.92"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.476", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.16"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.54", "ciUpperLimit": "0.85"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.243", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.88", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.70", "ciUpperLimit": "1.09"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.027", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "0.97"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.497", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.94", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.79", "ciUpperLimit": "1.12"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.60", "ciUpperLimit": "0.84"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.126", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.73", "ciUpperLimit": "1.04"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "0.85"}]}, {"type": "SECONDARY", "title": "Annual Rate of Asthma Exacerbations by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per year", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"title": "Moderate or severe asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "lowerLimit": "0.39", "upperLimit": "0.54"}, {"groupId": "OG001", "value": "0.58", "lowerLimit": "0.50", "upperLimit": "0.67"}, {"groupId": "OG002", "value": "0.54", "lowerLimit": "0.47", "upperLimit": "0.63"}, {"groupId": "OG003", "value": "0.67", "lowerLimit": "0.58", "upperLimit": "0.77"}, {"groupId": "OG004", "value": "0.72", "lowerLimit": "0.63", "upperLimit": "0.82"}]}]}, {"title": "Severe asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.26", "lowerLimit": "0.22", "upperLimit": "0.31"}, {"groupId": "OG001", "value": "0.38", "lowerLimit": "0.32", "upperLimit": "0.45"}, {"groupId": "OG002", "value": "0.33", "lowerLimit": "0.28", "upperLimit": "0.39"}, {"groupId": "OG003", "value": "0.41", "lowerLimit": "0.35", "upperLimit": "0.48"}, {"groupId": "OG004", "value": "0.45", "lowerLimit": "0.39", "upperLimit": "0.53"}]}]}, {"title": "All (mild, moderate, severe) asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.74", "lowerLimit": "0.64", "upperLimit": "0.85"}, {"groupId": "OG001", "value": "0.86", "lowerLimit": "0.75", "upperLimit": "0.98"}, {"groupId": "OG002", "value": "0.93", "lowerLimit": "0.82", "upperLimit": "1.06"}, {"groupId": "OG003", "value": "0.98", "lowerLimit": "0.86", "upperLimit": "1.11"}, {"groupId": "OG004", "value": "1.23", "lowerLimit": "1.08", "upperLimit": "1.39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.120", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.68", "ciUpperLimit": "1.04"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.52", "ciUpperLimit": "0.78"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.170", "statisticalMethod": "Generalized linear mode\u00f1", "paramType": "Rate ratio", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.71", "ciUpperLimit": "1.06"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.041", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.81", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "0.99"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.050", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "1.00"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.58", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.45", "ciUpperLimit": "0.73"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.531", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.74", "ciUpperLimit": "1.17"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.117", "statisticalMethod": "Linear generalized model", "paramType": "Rate ratio", "paramValue": "0.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "1.05"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.016", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.66", "ciUpperLimit": "0.96"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.50", "ciUpperLimit": "0.72"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.161", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.72", "ciUpperLimit": "1.06"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "Generalized linear model", "paramType": "Rate ratio", "paramValue": "0.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.58", "ciUpperLimit": "0.84"}]}, {"type": "SECONDARY", "title": "Duration in Days of Asthma Exacerbations by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"title": "Moderate or severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "10.73"}, {"groupId": "OG001", "value": "5.6", "spread": "12.87"}, {"groupId": "OG002", "value": "6.7", "spread": "20.52"}, {"groupId": "OG003", "value": "7.1", "spread": "17.17"}, {"groupId": "OG004", "value": "8.1", "spread": "20.63"}]}]}, {"title": "Severe asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "7.31"}, {"groupId": "OG001", "value": "4.1", "spread": "11.18"}, {"groupId": "OG002", "value": "4.9", "spread": "19.07"}, {"groupId": "OG003", "value": "4.5", "spread": "10.54"}, {"groupId": "OG004", "value": "5.8", "spread": "18.24"}]}]}, {"title": "All (mild, moderate, severe) asthma exacerbation", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.0", "spread": "16.02"}, {"groupId": "OG001", "value": "8.1", "spread": "20.51"}, {"groupId": "OG002", "value": "10.7", "spread": "28.70"}, {"groupId": "OG003", "value": "9.6", "spread": "21.76"}, {"groupId": "OG004", "value": "12.8", "spread": "29.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.183", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.155", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Moderate or severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.007", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.172", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.241", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Severe asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.033", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.095", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "0.090", "statisticalMethod": "van Elteren test"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "All (mild, moderate, severe) asthma exacerbation", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "van Elteren test"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category", "description": "The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"title": "Moderate or severe asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.2"}, {"groupId": "OG001", "value": "32.5"}, {"groupId": "OG002", "value": "31.8"}, {"groupId": "OG003", "value": "35.9"}, {"groupId": "OG004", "value": "39.7"}]}]}, {"title": "Severe asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.8"}, {"groupId": "OG001", "value": "24.6"}, {"groupId": "OG002", "value": "23.2"}, {"groupId": "OG003", "value": "27.3"}, {"groupId": "OG004", "value": "29.7"}]}]}, {"title": "All (mild, moderate, severe) asthma exacerbation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "615"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "40.2"}, {"groupId": "OG001", "value": "40.2"}, {"groupId": "OG002", "value": "41.9"}, {"groupId": "OG003", "value": "44.0"}, {"groupId": "OG004", "value": "50.5"}]}]}]}, {"type": "SECONDARY", "title": "Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation", "description": "Time from start of treatment until the first event (permanent discontinuation of study medication due to asthma exacerbation) or censoring. Patients without the event were considered as censored at the date of last treatment + 1 day. For patients having the event, the date of the discontinuation of study medication was considered to calculate the time to event.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "52 weeks on average, up to 416 days", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "367.0", "lowerLimit": "11", "upperLimit": "416"}, {"groupId": "OG001", "value": "367.0", "lowerLimit": "2", "upperLimit": "399"}, {"groupId": "OG002", "value": "367.0", "lowerLimit": "3", "upperLimit": "411"}, {"groupId": "OG003", "value": "367.0", "lowerLimit": "2", "upperLimit": "408"}, {"groupId": "OG004", "value": "367.0", "lowerLimit": "2", "upperLimit": "416"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.314", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "1.96"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.055", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.08", "ciUpperLimit": "1.03"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.306", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.25", "ciUpperLimit": "1.54"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.566", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.30", "ciUpperLimit": "1.94"}]}, {"type": "SECONDARY", "title": "Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations", "description": "The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "prednisone-equivalent milligram", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "616"}, {"groupId": "OG002", "value": "611"}, {"groupId": "OG003", "value": "607"}, {"groupId": "OG004", "value": "612"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.4", "spread": "169.76"}, {"groupId": "OG001", "value": "72.0", "spread": "211.41"}, {"groupId": "OG002", "value": "73.2", "spread": "235.90"}, {"groupId": "OG003", "value": "82.5", "spread": "208.36"}, {"groupId": "OG004", "value": "86.0", "spread": "199.79"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks", "description": "All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline, 26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "590"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "578"}, {"groupId": "OG003", "value": "580"}, {"groupId": "OG004", "value": "579"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "590"}, {"groupId": "OG001", "value": "577"}, {"groupId": "OG002", "value": "578"}, {"groupId": "OG003", "value": "580"}, {"groupId": "OG004", "value": "579"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.5", "spread": "1.32"}, {"groupId": "OG001", "value": "19.5", "spread": "1.33"}, {"groupId": "OG002", "value": "23.3", "spread": "1.33"}, {"groupId": "OG003", "value": "18.2", "spread": "1.33"}, {"groupId": "OG004", "value": "19.6", "spread": "1.33"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "583"}, {"groupId": "OG001", "value": "574"}, {"groupId": "OG002", "value": "576"}, {"groupId": "OG003", "value": "576"}, {"groupId": "OG004", "value": "578"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.0", "spread": "1.36"}, {"groupId": "OG001", "value": "21.9", "spread": "1.36"}, {"groupId": "OG002", "value": "24.9", "spread": "1.36"}, {"groupId": "OG003", "value": "20.8", "spread": "1.37"}, {"groupId": "OG004", "value": "21.8", "spread": "1.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.645", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.2", "ciUpperLimit": "2.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.74"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.095", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.5", "ciUpperLimit": "6.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.73"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.460", "statisticalMethod": "LMM", "paramType": "LMM", "paramValue": "1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.1", "ciUpperLimit": "4.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.75"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 26", "nonInferiorityType": "SUPERIORITY", "pValue": "0.971", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.5", "ciUpperLimit": "3.4", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.75"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.963", "statisticalMethod": "LMM", "paramType": "LMM", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.4", "ciUpperLimit": "3.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.075", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "3.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.3", "ciUpperLimit": "6.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.77"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.517", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "1.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "4.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.79"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 52", "nonInferiorityType": "SUPERIORITY", "pValue": "0.956", "statisticalMethod": "LMM", "paramType": "LS Mean", "paramValue": "0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.4", "ciUpperLimit": "3.6", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.78"}]}, {"type": "SECONDARY", "title": "Asthma Quality of Life Questionnaire (AQLQ) at Week 52", "description": "AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:\n\n* Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)\n* Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)\n* Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)\n* Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)\n* Overall Score = Mean of Items 1 to 32 (32 items) The overall AQLQ score reported below is the mean of all 32 responses and ranges from 1 to 7, where higher scores indicate better quality of life.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "606"}, {"groupId": "OG001", "value": "593"}, {"groupId": "OG002", "value": "595"}, {"groupId": "OG003", "value": "599"}, {"groupId": "OG004", "value": "594"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.555", "spread": "0.0354"}, {"groupId": "OG001", "value": "5.445", "spread": "0.0358"}, {"groupId": "OG002", "value": "5.535", "spread": "0.0356"}, {"groupId": "OG003", "value": "5.499", "spread": "0.0358"}, {"groupId": "OG004", "value": "5.495", "spread": "0.0357"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.690", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.020", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.078", "ciUpperLimit": "0.118", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0502"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.232", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.060", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.038", "ciUpperLimit": "0.159", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0502"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.285", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.054", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.153", "ciUpperLimit": "0.045", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0506"}, {"groupIds": ["OG001", "OG004"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.319", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "-0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.150", "ciUpperLimit": "0.049", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0505"}]}, {"type": "SECONDARY", "title": "Pre-dose FEV1 at Weeks 4 and 12", "description": "Pre-dose FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.", "populationDescription": "FAS including patients with a valid measurement for the outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "litres", "timeFrame": "4 weeks, 12 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "606"}, {"groupId": "OG001", "value": "594"}, {"groupId": "OG002", "value": "592"}, {"groupId": "OG003", "value": "596"}, {"groupId": "OG004", "value": "598"}]}], "classes": [{"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "598"}, {"groupId": "OG001", "value": "573"}, {"groupId": "OG002", "value": "573"}, {"groupId": "OG003", "value": "579"}, {"groupId": "OG004", "value": "577"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.032", "spread": "0.0122"}, {"groupId": "OG001", "value": "1.983", "spread": "0.0123"}, {"groupId": "OG002", "value": "1.963", "spread": "0.0124"}, {"groupId": "OG003", "value": "1.950", "spread": "0.0123"}, {"groupId": "OG004", "value": "1.887", "spread": "0.0123"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "580"}, {"groupId": "OG001", "value": "569"}, {"groupId": "OG002", "value": "573"}, {"groupId": "OG003", "value": "562"}, {"groupId": "OG004", "value": "568"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.024", "spread": "0.0134"}, {"groupId": "OG001", "value": "1.994", "spread": "0.0135"}, {"groupId": "OG002", "value": "1.966", "spread": "0.0135"}, {"groupId": "OG003", "value": "1.944", "spread": "0.0136"}, {"groupId": "OG004", "value": "1.907", "spread": "0.0135"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.068", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.036", "ciUpperLimit": "0.101", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0166"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.145", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.113", "ciUpperLimit": "0.177", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0165"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.049", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.033", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.000", "ciUpperLimit": "0.066", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0167"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.096", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.064", "ciUpperLimit": "0.129", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0166"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.002", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.058", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.022", "ciUpperLimit": "0.094", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0184"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.117", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.081", "ciUpperLimit": "0.153", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0183"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.007", "statisticalMethod": "MMRM", "paramType": "LS Mean", "paramValue": "0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.013", "ciUpperLimit": "0.086", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0185"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "statisticalMethod": "MMRM", "paramType": "MMRM", "paramValue": "0.087", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.051", "ciUpperLimit": "0.123", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0184"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes", "description": "A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee.", "populationDescription": "SAF", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG002", "title": "QMF149 150/320 \u00b5g o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG003", "title": "QMF149 150/160 \u00b5g o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device"}, {"id": "OG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "616"}, {"groupId": "OG001", "value": "617"}, {"groupId": "OG002", "value": "613"}, {"groupId": "OG003", "value": "608"}, {"groupId": "OG004", "value": "618"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.4"}, {"groupId": "OG001", "value": "2.5"}, {"groupId": "OG002", "value": "1.9"}, {"groupId": "OG003", "value": "1.6"}, {"groupId": "OG004", "value": "1.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days (52 weeks on average, up to 416 days).", "description": "Any signs or symptoms that occurs during study treatment plus the 30 days post treatment.", "eventGroups": [{"id": "EG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "deathsNumAffected": 2, "deathsNumAtRisk": 616, "seriousNumAffected": 46, "seriousNumAtRisk": 616, "otherNumAffected": 367, "otherNumAtRisk": 616}, {"id": "EG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "deathsNumAffected": 1, "deathsNumAtRisk": 617, "seriousNumAffected": 49, "seriousNumAtRisk": 617, "otherNumAffected": 387, "otherNumAtRisk": 617}, {"id": "EG002", "title": "QMF149 150/320 \u03bcg o.d.", "description": "QMF149 150/320 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "deathsNumAffected": 4, "deathsNumAtRisk": 613, "seriousNumAffected": 52, "seriousNumAtRisk": 613, "otherNumAffected": 377, "otherNumAtRisk": 613}, {"id": "EG003", "title": "QMF149 150/160 \u03bcg o.d.", "description": "QMF149 150/160 \u03bcg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device", "deathsNumAffected": 0, "deathsNumAtRisk": 608, "seriousNumAffected": 38, "seriousNumAtRisk": 608, "otherNumAffected": 392, "otherNumAtRisk": 608}, {"id": "EG004", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d.", "description": "Salmeterol xinafoate /fluticasone propionate 50/500 \u03bcg twice daily (b.i.d.) delivered via Accuhaler\u00ae", "deathsNumAffected": 0, "deathsNumAtRisk": 618, "seriousNumAffected": 39, "seriousNumAtRisk": 618, "otherNumAffected": 419, "otherNumAtRisk": 618}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Immune thrombocytopenic purpura", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Acute cardiac event", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cardiac tamponade", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Middle ear effusion", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Otorrhoea", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Optic ischaemic neuropathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Gastrointestinal angiodysplasia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Intra-abdominal fluid collection", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Large intestine perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Peritoneal adhesions", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Proctitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Rectal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Rectal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Hepatic cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Liver injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Primary biliary cholangitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Steatohepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Sarcoidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 618}]}, {"term": "Bursitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 618}]}, {"term": "Cholecystitis infective", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Dengue fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "HIV infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Infectious pleural effusion", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 618}]}, {"term": "Mastoiditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Otitis media chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Peritonitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 618}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pulmonary tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Salpingitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Lumbar vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Meniscus injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Post procedural discomfort", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Skin abrasion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Transaminases increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Jaw disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pathological fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Spinal deformity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Acute leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Central nervous system lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Chronic lymphocytic leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Liposarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ovarian adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Salivary gland adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Soft tissue sarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Uterine cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Alcoholic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cervicobrachial syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hypertensive encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ischaemic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Transient global amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Calculus urethral", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Nephritis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Cystocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Endometriosis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Postmenopausal haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Uterine polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 618}]}, {"term": "Bronchitis chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Haemothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Nasal septum deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Sinus polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 618}]}, {"term": "Angiopathy", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Aortic dissection", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Aortic dissection rupture", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Haemorrhagic vasculitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 618}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Thrombophlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}, {"term": "Varicose vein", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 618}]}], "otherEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 15, "numAtRisk": 618}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 49, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 48, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 46, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 44, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 55, "numAtRisk": 618}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 23, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 26, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 25, "numAtRisk": 618}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 22, "numAtRisk": 618}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 64, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 76, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 73, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 64, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 83, "numAtRisk": 618}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 20, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 19, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 20, "numAtRisk": 618}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 29, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 22, "numAtRisk": 618}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 20, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 11, "numAtRisk": 618}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 14, "numAtRisk": 618}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 45, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 52, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 48, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 52, "numAtRisk": 618}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 27, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 28, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 29, "numAtRisk": 618}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 13, "numAtRisk": 618}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 38, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 26, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 47, "numAtRisk": 618}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 12, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 10, "numAtRisk": 618}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 16, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 14, "numAtRisk": 618}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 34, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 25, "numAtRisk": 618}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 243, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 242, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 249, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 265, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 306, "numAtRisk": 618}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 14, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 15, "numAtRisk": 618}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 10, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 12, "numAtRisk": 618}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 20, "numAtRisk": 618}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 616}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 617}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 613}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 608}, {"groupId": "EG004", "numAffected": 23, "numAtRisk": 618}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-09-28", "uploadDate": "2020-06-12T05:41", "filename": "SAP_000.pdf", "size": 453337}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-12-18", "uploadDate": "2020-07-15T11:35", "filename": "Prot_001.pdf", "size": 2603175}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Slovenia"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "relevance": "LOW"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}